Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 5/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6690925 | 0.83 | KDM4E (0.43) | LMNAKDM4EALDH1A1CYP3A4GABRB3 | |
| SCHEMBL6692931 | 0.83 | ADAMTS5 (0.42) | LMNAKDM4EALDH1A1CYP3A4GABRB3 | |
| SCHEMBL631588 | 0.81 | LMNA (0.41) | LMNAKDM4EALDH1A1CYP3A4GABRB3 | |
| SCHEMBL630914 | 0.81 | LMNA (0.41) | LMNAKDM4EALDH1A1CYP3A4GABRB3 | |
| SCHEMBL6691745 | 0.81 | ADAMTS5 (0.37) | LMNAKDM4EALDH1A1CYP3A4GABRB3 | |
| SCHEMBL23354823 | 0.81 | ADAMTS5 (0.40) | LMNAKDM4EALDH1A1CYP3A4GABRB3 | |
| SCHEMBL6700471 | 0.80 | ADAMTS5 (0.40) | KDM4EALDH1A1CYP3A4GABRB3OPRD1 | |
| SCHEMBL11413172 | 0.80 | CYP3A4 (0.58) | LMNAKDM4EALDH1A1CYP3A4GABRB3 | |
| Hydrochloric Acid SCHEMBL23353975 | 0.79 | ADAMTS5 (0.39) | LMNAKDM4EALDH1A1CYP3A4GABRB3 | |
| Hydrochloric Acid SCHEMBL31676880 | 0.79 | ADAMTS5 (0.39) | LMNAKDM4EALDH1A1CYP3A4GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0534774-A1 | 5,5-Dialkyl hydantoins for promoted acid gas scrubbing processes | EXXON CHEMICAL PATENTS INC. (US) | 1993-03-31 | — | — | EP | claimed |
| EP-3103797-B1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20170342094-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2017-11-30 | — | — | US | disclosed |
| US-9670150-B2 | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3103797-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2776403-B1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2776403-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8729096-B2 | Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators | ALLERGAN, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130217720-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR 2 MODULATORS | ALLERGAN, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8492556-B2 | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| WO-2013071203-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20040200780-A1 | Methods and systems for uniform control of bromine concentrations in water | HOWARTH JONATHAN N (US) | 2004-10-14 | — | — | US | disclosed |
| US-6749758-B2 | Methods and systems for uniform-control of bromine concentrations in water | ALBEMARLE CORPORATION | 2004-06-15 | — | — | US | disclosed |
| WO-2003047345-A2 | METHOD FOR UNIFORM CONTROL OF BROMINE CONCENTRATIONS IN BIOCIDAL WATER | ALBEMARLE CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| US-20030102271-A1 | Methods and systems for uniform control of bromine concentrations in water | ALBEMARLE CORPORATION | 2003-06-05 | — | — | US | disclosed |
| EP-0534774-A1 | 5,5-Dialkyl hydantoins for promoted acid gas scrubbing processes | EXXON CHEMICAL PATENTS INC. (US) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR2, FPR3 | LMNA 3779/4885KDM4E 4470/4885ALDH1A1 3811/4885 |
| US-20170342094-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | LMNA 3544/4885KDM4E 1574/4885ALDH1A1 1152/4885 |
| US-20130217720-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR 2 MODULATORS | FPR2, FPR1, FPR3 | LMNA 4190/4885KDM4E 4612/4885ALDH1A1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.